Fredrik Lehmann

Fredrik Lehmann has an extensive work experience spanning several industries. Fredrik currently serves as a Venture Partner at Industrifonden since October 2022. Fredrik is also a Board Member at Teitur Trophics since March 2023 and at Guard Therapeutics since December 2022. Additionally, they hold the position of Board Member at AnaCardio since October 2022.

In the past, Fredrik co-founded and served as the Chairman of the Board at Synartro since its establishment in 2011. Fredrik was also a Member of the Board of Directors at Sprint Bioscience since May 2019 and a Drug Development Consultant at OT Pharma starting from January 2015.

Fredrik's earlier roles include Head of Research and CMC at Oncopeptides AB from November 2008 until September 2022. Fredrik served as the CEO at EpiEndo Pharmaceuticals from September 2018 to January 2021. Prior to that, they held the position of General Manager at Recipharm OT Chemistry AB from June 2016 to March 2018.

Fredrik Lehmann completed their education in a chronological manner. Fredrik started their education at Uppsala University from 1995 to 2000, where they pursued a degree known as Fil Mag in Organic Chemistry. Following that, they enrolled at the University of Gothenburg from 2002 to 2007, where they earned a PhD in Medicinal Chemistry. Most recently, from 2020 to 2021, Fredrik attended the Stockholm School of Economics and pursued an MBA, although the degree name is not specified.